Simplify Asset Management Inc. bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 192,339 shares of the company’s stock, valued at approximately $1,808,000.
Several other institutional investors also recently modified their holdings of KYTX. Bank of America Corp DE raised its position in shares of Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after acquiring an additional 6,400 shares during the period. Cubist Systematic Strategies LLC grew its holdings in Kyverna Therapeutics by 31.1% during the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock valued at $132,000 after purchasing an additional 16,267 shares during the period. AQR Capital Management LLC bought a new stake in Kyverna Therapeutics in the first quarter valued at approximately $137,000. Rhumbline Advisers increased its stake in Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Kyverna Therapeutics in the second quarter worth $107,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. decreased their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Wall Street Zen upgraded Kyverna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright boosted their target price on Kyverna Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kyverna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.
Kyverna Therapeutics Price Performance
KYTX stock opened at $8.67 on Monday. The business has a 50-day moving average of $9.05 and a 200-day moving average of $8.44. Kyverna Therapeutics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $13.67. The stock has a market capitalization of $527.05 million, a P/E ratio of -2.64 and a beta of 2.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. On average, sell-side analysts anticipate that Kyverna Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.
Kyverna Therapeutics Profile
Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.
The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.
Featured Stories
- Five stocks we like better than Kyverna Therapeutics
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding KYTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report).
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
